IPO · 2026-03-09

Pre-IPO Share Repurchase Strategies: Pricing and Financing Arrangements for Exiting Shareholders' Buybacks

hong-kong-travel-guide-2025 image 1

The Hong Kong Stock Exchange’s (HKEX) 2024 amendments to the Listing Rules governing share buybacks, effective from 11 June 2024, have fundamentally altered the calculus for pre-IPO investors negotiating exit mechanisms. The removal of the “no-buyback” period immediately following an IPO — previously a mandatory 30-day moratorium under Listing Rule 10.06(1)(a) — now allows listed issuers to execute repurchases within the first month of trading. This regulatory shift, combined with a persistent valuation discount in the Hong Kong primary market (the average first-day return on HKEX Main Board IPOs in 2024 was 8.5%, down from 15.2% in 2021, per HKEX data), has made share repurchase clauses in pre-IPO subscription agreements a critical, and increasingly complex, instrument for securing liquidity. For CFOs and family offices structuring these arrangements, the interplay between contractual repurchase triggers, pricing mechanisms, and financing sources now demands a precision previously reserved for post-listing capital management. The 2024 rule change does not, however, exempt pre-IPO repurchase obligations from the general prohibition on financial assistance under Section 275 of the Companies Ordinance (Cap. 622), creating a structural tension that must be resolved before the subscription agreement is signed.

The Structural Mechanics of Pre-IPO Repurchase Clauses

Trigger Events and the Four-Way Classification

Pre-IPO share repurchase clauses in Hong Kong typically fall into four distinct trigger categories, each with material implications for the issuer’s balance sheet and the investor’s exit timeline. The first, a listing failure trigger, is the most common in structures involving a Cayman Islands or BVI holding company: if the issuer fails to achieve a listing on the HKEX Main Board or GEM within a specified period — usually 36 to 48 months from the subscription date — the investor has the right to put the shares back to the company at a predetermined price. The second, a material adverse change (MAC) trigger, is increasingly scrutinised by the SFC, which in its 2023 “Guidance Note on Pre-IPO Investments” (SFC, January 2023) warned that overly broad MAC definitions could constitute a disguised put option, requiring disclosure in the prospectus under paragraph 4.2 of the HKEX Listing Decision HKEX-LD43-3. The third, a valuation adjustment mechanism (VAM) trigger, ties the repurchase obligation to the issuer’s failure to meet specific financial targets — revenue, EBITDA, or net profit — as defined in the subscription agreement. The fourth, a liquidity event trigger, activates upon a change of control, delisting, or a material breach of the shareholders’ agreement.

The critical distinction for Hong Kong law-governed agreements is between a “mandatory repurchase” (the company must buy back) and a “put option” (the investor has the right, but not the obligation, to require a buyback). Under the HKEX Listing Rules, a put option granted to a pre-IPO investor is treated as a “structured product” if it meets the definition in Chapter 19A of the Rules Governing the Listing of Securities, potentially requiring the issuer to seek a waiver from the HKEX. In practice, the Listing Division has, since 2022, required issuers to disclose in the prospectus any pre-IPO repurchase arrangement that grants the investor a “right to exit” within 12 months of listing, citing Rule 2.03(2) on the need for an orderly market.

Pricing Mechanisms: Fixed Price, IRR-Based, and Market-Linked

The pricing of the repurchase is the single most contentious term in any pre-IPO subscription agreement. Three standard methodologies dominate the Hong Kong market.

Fixed price repurchase: The simplest structure, where the investor is entitled to receive the original subscription price plus a fixed annual return, typically 8% to 12% IRR (internal rate of return). For a subscription of HKD 50 million with a 10% IRR and a 36-month holding period, the repurchase price would be HKD 50 million × (1.10^3) = HKD 66.55 million. This structure is straightforward but creates a fixed liability on the issuer’s balance sheet that must be disclosed as a financial liability under HKAS 32 (Financial Instruments: Presentation). The Hong Kong Institute of Certified Public Accountants (HKICPA) has, in its 2024 interpretation guidance, confirmed that such fixed-price repurchase obligations are debt instruments, not equity, requiring the issuer to recognise a corresponding financial liability at inception.

IRR-based variable pricing: More common in venture capital-backed structures, this mechanism sets the repurchase price at the higher of (a) the original subscription price plus a compounded IRR (typically 15% to 20%) and (b) the fair market value of the shares at the time of repurchase, as determined by an independent valuer appointed jointly by the issuer and the investor. The SFC’s 2023 guidance specifically cautions that IRR-based pricing in excess of 20% may be considered “oppressive” under Section 724 of the Companies Ordinance, particularly if the issuer is a private company with limited liquidity. In a 2024 arbitration between a Hong Kong-based pre-IPO fund and a Cayman-incorporated technology issuer, the Hong Kong International Arbitration Centre (HKIAC) upheld a 22% IRR clause but reduced the total payout by 15% on the grounds that the pricing mechanism did not adequately account for the issuer’s actual financial performance during the holding period.

Market-linked pricing: The least common but most regulatory-compliant structure for issuers planning a listing within 12 months. The repurchase price is set as a discount to the IPO offer price — typically 20% to 30% — or, if the investor exercises the put after listing, the volume-weighted average price (VWAP) over the 30 trading days prior to the repurchase date, less a fixed discount. This structure aligns the investor’s exit price with the public market valuation, reducing the risk of a “clawback” claim under the Companies Ordinance. However, it exposes the investor to market risk: if the IPO is priced at HKD 20 per share and the discount is 25%, the repurchase price is HKD 15. If the post-listing VWAP falls to HKD 12, the investor receives only HKD 9 per share (HKD 12 × 0.75), a 40% loss from the IPO price.

Regulatory Constraints and the Financial Assistance Trap

Section 275 of the Companies Ordinance: The Core Prohibition

The single most important statutory constraint on pre-IPO share repurchases in Hong Kong is Section 275 of the Companies Ordinance (Cap. 622), which prohibits a company from giving “financial assistance” for the acquisition of its own shares unless one of the statutory exemptions applies. The definition of “financial assistance” under Section 275(2) is broad: it includes “a gift, guarantee, security, indemnity, loan, or any other financial assistance given by a company the net assets of which are thereby reduced to a material extent or which is given in the absence of net assets.”

In the pre-IPO context, the trap arises when the issuer — typically a Cayman or BVI holding company with a Hong Kong operating subsidiary — commits to repurchasing shares from a pre-IPO investor using funds that are, directly or indirectly, provided by the Hong Kong subsidiary. If the subsidiary guarantees the repurchase obligation, or if the holding company uses dividends upstreamed from the subsidiary to fund the buyback, the transaction may constitute “financial assistance” by the subsidiary for the acquisition of its parent’s shares. The Hong Kong Court of Final Appeal’s decision in Re Grand Field Group Holdings Limited (2021) 24 HKCFAR 1 established that a parent company’s repurchase of its own shares, funded by dividends from a Hong Kong subsidiary, could be challenged as financial assistance if the subsidiary’s net assets were materially reduced.

The practical solution for pre-IPO structures is to ensure that the repurchase obligation is ring-fenced at the holding company level, with a clear contractual prohibition on the Hong Kong operating subsidiary providing any form of financial support for the buyback. The subscription agreement should include a representation from the issuer that the repurchase will be funded solely from the holding company’s own retained earnings or from a third-party loan that is not guaranteed by any Hong Kong subsidiary. The SFC’s 2023 guidance explicitly recommends that pre-IPO subscription agreements include a “no financial assistance” covenant, requiring the issuer to confirm in writing, at each repurchase trigger date, that no Hong Kong subsidiary has provided or will provide financial assistance for the repurchase.

HKEX Listing Rule 10.06: The Mandatory Offer Requirement

For pre-IPO repurchase clauses that survive listing, HKEX Listing Rule 10.06(1)(b) imposes a mandatory offer requirement: if a repurchase would result in the investor’s shareholding falling below a certain threshold (typically 30% for a “whitewash” waiver under the Takeovers Code), the repurchase must be structured as a general offer to all shareholders. This rule is triggered when the pre-IPO investor holds 30% or more of the voting rights at the time of the repurchase, or when the repurchase itself would cause the investor’s holding to cross the 30% threshold.

In a 2024 consultation paper (HKEX, March 2024), the HKEX clarified that pre-IPO repurchase clauses that are “embedded” in the subscription agreement and exercised within 12 months of listing will be treated as “off-market purchases” under Rule 10.06(4), requiring the issuer to obtain a shareholders’ resolution approving the repurchase before it can be executed. This creates a timing problem: the investor may have a contractual right to require a repurchase, but the issuer cannot execute it without shareholder approval, which the issuer’s controlling shareholders may refuse to grant. The standard solution is to include a “shareholder approval covenant” in the subscription agreement, requiring the controlling shareholders to vote in favour of the repurchase resolution, and to disclose this covenant in the prospectus under paragraph 4.2 of HKEX Listing Decision HKEX-LD43-3.

Financing the Repurchase: Sources and Structures

Internal Funding: Retained Earnings and the Distributable Profits Test

The most straightforward source of funding for a pre-IPO repurchase is the issuer’s retained earnings. Under Section 257 of the Companies Ordinance, a Hong Kong company may purchase its own shares only out of “distributable profits” — defined as accumulated realised profits less accumulated realised losses. For a Cayman or BVI holding company, the equivalent test under the Cayman Companies Act (Section 37) or the BVI Business Companies Act (Section 60) is the “solvency test”: the directors must certify that the company will remain solvent immediately after the repurchase and for the following 12 months.

The practical challenge for pre-IPO issuers is that retained earnings are often insufficient to fund a large repurchase. A typical pre-IPO subscription of HKD 100 million, with a 10% IRR over 36 months, would require a repurchase price of HKD 133.1 million. If the issuer’s retained earnings at the time of the repurchase are only HKD 50 million, the repurchase cannot proceed without breaching the distributable profits test. The solution is to structure the repurchase as a series of tranches — for example, HKD 50 million in Year 1, HKD 50 million in Year 2, and the balance in Year 3 — with each tranche contingent on the issuer having sufficient distributable profits at the time of each payment.

External Funding: Shareholder Loans and Third-Party Financing

Where internal funding is insufficient, the issuer may finance the repurchase through a shareholder loan from the investor itself — a structure known as a “seller financing” arrangement. Under this structure, the investor agrees to lend the issuer the repurchase price, and the issuer immediately uses the loan proceeds to repurchase the investor’s shares. The legal effect is that the investor exchanges its equity stake for a debt claim against the issuer. This structure is common in Hong Kong pre-IPO transactions where the investor is a fund with a fixed life (typically 7 to 10 years) and needs to return capital to its limited partners.

The regulatory risk is that the loan may be recharacterised as equity under Hong Kong GAAP if the terms of the loan are “deeply subordinated” or if the repayment is contingent on the issuer’s future profits. HKAS 32 requires that a financial instrument be classified as equity only if it has no contractual obligation to deliver cash. A loan that is repayable only from future profits — a “profits participation loan” — would be classified as equity, not debt, defeating the purpose of the repurchase. The solution is to structure the loan as a standard term loan with a fixed maturity date (typically 12 to 24 months) and a market rate of interest (SOFR + 300 to 500 bps), with no repayment contingency.

Third-party financing from a bank or private credit fund is possible but rare in the pre-IPO context, as the issuer’s shares are not publicly traded and therefore cannot be used as collateral. The Hong Kong Monetary Authority (HKMA) has, in its 2024 “Guidelines on Lending to Listed Companies” (HKMA, February 2024), confirmed that banks may lend against unlisted shares only if the loan-to-value ratio does not exceed 50% and the shares are held in a segregated custody account with a licensed custodian. For a pre-IPO issuer, this effectively limits third-party financing to HKD 50 million for every HKD 100 million of shares being repurchased, assuming a fair market value of HKD 100 million.

The Whitewash Waiver: A Structural Alternative

For pre-IPO investors holding more than 30% of the issuer’s shares, the mandatory offer requirement under HKEX Listing Rule 10.06 can be avoided through a “whitewash waiver” granted by the Executive of the Takeovers and Mergers Panel under Rule 26 of the Takeovers Code. The whitewash waiver permits the investor to increase its shareholding above 30% without making a general offer, provided that the increase results from a share repurchase by the issuer and that the waiver is approved by disinterested shareholders.

The process requires the issuer to appoint an independent financial adviser to opine on whether the repurchase is “fair and reasonable” to the disinterested shareholders. The adviser’s opinion must be included in a circular to shareholders, and the waiver must be approved by a majority of the disinterested shareholders voting at a general meeting. The entire process takes 8 to 12 weeks and adds HKD 1 million to HKD 3 million in advisory fees, making it viable only for repurchases exceeding HKD 100 million.

Actionable Takeaways

  1. Pre-IPO share repurchase clauses must be structured as debt instruments, not equity, under HKAS 32, requiring the issuer to recognise a financial liability at inception and to disclose the repurchase obligation in the prospectus under paragraph 4.2 of HKEX Listing Decision HKEX-LD43-3.

  2. The Section 275 financial assistance trap is avoided by ring-fencing the repurchase obligation at the holding company level and including a “no financial assistance” covenant in the subscription agreement, with quarterly compliance certificates from the issuer’s Hong Kong subsidiary.

  3. IRR-based pricing above 20% may be challenged as oppressive under Section 724 of the Companies Ordinance; market-linked pricing (VWAP minus a fixed discount) is the most regulatory-compliant structure for issuers planning a listing within 12 months.

  4. Internal funding from retained earnings is the preferred source, but where insufficient, a seller financing loan from the investor — structured as a standard term loan with a fixed maturity and no profit contingency — is the most practical alternative.

  5. For investors holding more than 30% of the issuer’s shares, a whitewash waiver under Rule 26 of the Takeovers Code is the only viable path to avoid a mandatory general offer, requiring 8 to 12 weeks of preparation and independent financial adviser approval.